Objective: To observe the clinical effect of mild moxibustion for knee osteoarthritis (KOA) and to explore the role of mild moxibustion in relieving pain, reducing stiffness and improving joint dysfunction in patients...Objective: To observe the clinical effect of mild moxibustion for knee osteoarthritis (KOA) and to explore the role of mild moxibustion in relieving pain, reducing stiffness and improving joint dysfunction in patients with KOA. Methods: Eighty patients with KOA were randomly allocated into either a moxibustion group or a medication group by the random number table, with 40 cases in each group. The moxibustion group used mild moxibustion at Neixiyan (EX-LE 5), Dubi (ST 35), Xuehai (SP 10) and Liangqiu (ST 34), 30 min each time, 3 times a week;the medication group was given celecoxib capsule (celebrex), 0.2 g each time, once a day. Both groups were treated for 4 weeks. The visual analog scale (VAS) and Western Ontario and McMaster Universities osteoarthritis index (WOMAC) scores were evaluated before and after treatment. The efficacy of the two groups was compared after treatment. Results: After treatme nt, the overall efficacy of the moxibustion group was sign ificantly differ ent from that of the medication group (P<0.05). The VAS and WOMAC scores of the two groups were lower than those before treatment (both P<0.01). The changes in the VAS and WOMAC scores after treatment in the moxibustion group were significantly different from those in the medication group (both P<0.05). After treatment, in single item of WOMAC, the changes in pain and joint dysfunction in the moxibustion group were more statistically significant than those in the medication group (both P<0.05). Conclusion: Mild moxibustion and oral celebrex can reduce the VAS and WOMAC scores of patients with KOA. Mild moxibustion is superior to oral celebrex in relieving pain and improving joint function.展开更多
文摘Objective: To observe the clinical effect of mild moxibustion for knee osteoarthritis (KOA) and to explore the role of mild moxibustion in relieving pain, reducing stiffness and improving joint dysfunction in patients with KOA. Methods: Eighty patients with KOA were randomly allocated into either a moxibustion group or a medication group by the random number table, with 40 cases in each group. The moxibustion group used mild moxibustion at Neixiyan (EX-LE 5), Dubi (ST 35), Xuehai (SP 10) and Liangqiu (ST 34), 30 min each time, 3 times a week;the medication group was given celecoxib capsule (celebrex), 0.2 g each time, once a day. Both groups were treated for 4 weeks. The visual analog scale (VAS) and Western Ontario and McMaster Universities osteoarthritis index (WOMAC) scores were evaluated before and after treatment. The efficacy of the two groups was compared after treatment. Results: After treatme nt, the overall efficacy of the moxibustion group was sign ificantly differ ent from that of the medication group (P<0.05). The VAS and WOMAC scores of the two groups were lower than those before treatment (both P<0.01). The changes in the VAS and WOMAC scores after treatment in the moxibustion group were significantly different from those in the medication group (both P<0.05). After treatment, in single item of WOMAC, the changes in pain and joint dysfunction in the moxibustion group were more statistically significant than those in the medication group (both P<0.05). Conclusion: Mild moxibustion and oral celebrex can reduce the VAS and WOMAC scores of patients with KOA. Mild moxibustion is superior to oral celebrex in relieving pain and improving joint function.
